CA2560066A1 - Natural igm antibodies and inhibitors thereof - Google Patents

Natural igm antibodies and inhibitors thereof Download PDF

Info

Publication number
CA2560066A1
CA2560066A1 CA002560066A CA2560066A CA2560066A1 CA 2560066 A1 CA2560066 A1 CA 2560066A1 CA 002560066 A CA002560066 A CA 002560066A CA 2560066 A CA2560066 A CA 2560066A CA 2560066 A1 CA2560066 A1 CA 2560066A1
Authority
CA
Canada
Prior art keywords
seq
nucleic acid
antibody
peptide
igm
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002560066A
Other languages
English (en)
French (fr)
Inventor
Michael C. Carroll
Jr. Francis D. Moore
Herbert B. Hechtman
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
The Brigham and Women's Hospital Inc
Boston Children's Hospital
Harvard University
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Priority to CA2812132A priority Critical patent/CA2812132C/en
Publication of CA2560066A1 publication Critical patent/CA2560066A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
CA002560066A 2004-03-01 2005-03-01 Natural igm antibodies and inhibitors thereof Abandoned CA2560066A1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CA2812132A CA2812132C (en) 2004-03-01 2005-03-01 Natural igm antibodies and inhibitors thereof

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US54912304P 2004-03-01 2004-03-01
US60/549,123 2004-03-01
US58864804P 2004-07-16 2004-07-16
US60/588,648 2004-07-16
PCT/US2005/006276 WO2005085288A2 (en) 2004-03-01 2005-03-01 Natural igm antibodies and inhibitors thereof

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CA2812132A Division CA2812132C (en) 2004-03-01 2005-03-01 Natural igm antibodies and inhibitors thereof

Publications (1)

Publication Number Publication Date
CA2560066A1 true CA2560066A1 (en) 2005-09-15

Family

ID=34922704

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002560066A Abandoned CA2560066A1 (en) 2004-03-01 2005-03-01 Natural igm antibodies and inhibitors thereof

Country Status (9)

Country Link
US (5) US7442783B2 (enExample)
EP (2) EP1725659B1 (enExample)
JP (3) JP5557982B2 (enExample)
AT (1) ATE498010T1 (enExample)
AU (1) AU2005219839B9 (enExample)
CA (1) CA2560066A1 (enExample)
DE (1) DE602005026260D1 (enExample)
IL (1) IL177825A (enExample)
WO (1) WO2005085288A2 (enExample)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2560066A1 (en) 2004-03-01 2005-09-15 The Cbr Institute For Biomedical Research, Inc. Natural igm antibodies and inhibitors thereof
US20100136684A1 (en) * 2004-03-01 2010-06-03 Carroll Michael C Natural IgM Antibodies
CA2783563A1 (en) 2009-12-07 2011-06-16 Decimmune Therapeutics, Inc. Anti-inflammatory antibodies and uses therefor
WO2011153431A2 (en) * 2010-06-03 2011-12-08 Abraxis Bioscience, Llc Peripheral blood sparc antibodies and uses thereof
WO2014055392A2 (en) * 2012-10-01 2014-04-10 Decimmune Therapeutics, Inc. Method of protecting cardiac function
JP6162319B2 (ja) 2013-03-12 2017-07-12 デシミューン セラピューティクス，インコーポレイテッド ヒト化抗ｎ２抗体
JP6551825B2 (ja) * 2014-02-10 2019-07-31 公立大学法人首都大学東京 クロマチン構造制御剤

Family Cites Families (60)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
JPS6147500A (ja) 1984-08-15 1986-03-07 Res Dev Corp Of Japan キメラモノクロ−ナル抗体及びその製造法
EP0173494A3 (en) 1984-08-27 1987-11-25 The Board Of Trustees Of The Leland Stanford Junior University Chimeric receptors by dna splicing and expression
GB8422238D0 (en) 1984-09-03 1984-10-10 Neuberger M S Chimeric proteins
JPS61134325A (ja) 1984-12-04 1986-06-21 Teijin Ltd ハイブリツド抗体遺伝子の発現方法
US4683202A (en) 1985-03-28 1987-07-28 Cetus Corporation Process for amplifying nucleic acid sequences
US4683195A (en) 1986-01-30 1987-07-28 Cetus Corporation Process for amplifying, detecting, and/or-cloning nucleic acid sequences
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
US5266480A (en) 1986-04-18 1993-11-30 Advanced Tissue Sciences, Inc. Three-dimensional skin culture system
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
DE68927933T2 (de) 1988-09-02 1997-08-14 Dyax Corp Herstellung und auswahl von rekombinantproteinen mit verschiedenen bindestellen
EP0411060A4 (en) 1988-09-06 1991-04-03 Asarco Incorporated Method and burner for melting copper
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5096815A (en) 1989-01-06 1992-03-17 Protein Engineering Corporation Generation and selection of novel dna-binding proteins and polypeptides
US5198346A (en) 1989-01-06 1993-03-30 Protein Engineering Corp. Generation and selection of novel DNA-binding proteins and polypeptides
WO1991000906A1 (en) 1989-07-12 1991-01-24 Genetics Institute, Inc. Chimeric and transgenic animals capable of producing human antibodies
EP0502060A4 (en) 1989-11-13 1993-05-05 Affymax Technologies N.V. Spatially-addressable immobilization of anti-ligands on surfaces
AU7163091A (en) * 1989-12-12 1991-07-18 Biomedical Research Institute Novel malarial sporozoite peptide antigens
EP1690935A3 (en) 1990-01-12 2008-07-30 Abgenix, Inc. Generation of xenogeneic antibodies
US5427908A (en) 1990-05-01 1995-06-27 Affymax Technologies N.V. Recombinant library screening methods
ES2139598T3 (es) 1990-07-10 2000-02-16 Medical Res Council Procedimientos para la produccion de miembros de parejas de union especifica.
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
CA2090473A1 (en) 1990-08-29 1992-03-01 Robert M. Kay Homologous recombinatin in mammalian cells
ES2246502T3 (es) 1990-08-29 2006-02-16 Genpharm International, Inc. Animales no humanos transgenicos capaces de producir anticuerpos heterologos.
US5252714A (en) 1990-11-28 1993-10-12 The University Of Alabama In Huntsville Preparation and use of polyethylene glycol propionaldehyde
DE69129154T2 (de) 1990-12-03 1998-08-20 Genentech, Inc., South San Francisco, Calif. Verfahren zur anreicherung von proteinvarianten mit geänderten bindungseigenschaften
DK0562025T3 (da) 1990-12-06 2001-06-18 Affymetrix Inc Forbindelser og deres anvendelse i en binær syntesestrategi
DE69233697T2 (de) 1991-03-01 2008-01-24 Dyax Corp., Cambridge Verfahren zur Entwicklung von bindenden Mikroproteinen
PT100379B (pt) 1991-04-10 1999-01-29 Scripps Research Inst Bibliotecas de receptores heterodimericos usando fagomideos
DE4122599C2 (de) 1991-07-08 1993-11-11 Deutsches Krebsforsch Phagemid zum Screenen von Antikörpern
DE69233087T2 (de) 1991-11-22 2003-12-24 Affymetrix, Inc. (N.D.Ges.D.Staates Delaware) Verfahren zur Herstellung von Polymerarrays
US5233409A (en) 1992-02-25 1993-08-03 Schwab Karl W Color analysis of organic constituents in sedimentary rocks for thermal maturity
US5359115A (en) 1992-03-26 1994-10-25 Affymax Technologies, N.V. Methods for the synthesis of phosphonate esters
US5573905A (en) 1992-03-30 1996-11-12 The Scripps Research Institute Encoded combinatorial chemical libraries
US5288514A (en) 1992-09-14 1994-02-22 The Regents Of The University Of California Solid phase and combinatorial synthesis of benzodiazepine compounds on a solid support
HUT72495A (en) 1992-10-01 1996-05-28 Cold Spring Harbor Lab Complex combinatorial chemical libraries encoded with tags
US6174530B1 (en) 1993-05-05 2001-01-16 Gryphon Sciences Homogeneous polyoxime compositions and their preparation by parallel assembly
AU691811B2 (en) 1993-06-16 1998-05-28 Celltech Therapeutics Limited Antibodies
US5362899A (en) 1993-09-09 1994-11-08 Affymax Technologies, N.V. Chiral synthesis of alpha-aminophosponic acids
US6184344B1 (en) 1995-05-04 2001-02-06 The Scripps Research Institute Synthesis of proteins by native chemical ligation
US6376653B1 (en) 1998-09-28 2002-04-23 Smithkline Beecham Plc Tie2 antagonist antibodies
AU774841B2 (en) * 1998-12-03 2004-07-08 Targanta Therapeutics Inc. Development of novel anti-microbial agents based on bacteriophage genomics
NZ512941A (en) 1999-01-15 2003-09-26 Us Agriculture Length polymorphisms in microsatellite (simple sequence repeat - SSR) DNA markers and their use as genetic markers in pine
US6753314B1 (en) * 1999-04-01 2004-06-22 Curagen Corporation Protein-protein complexes and methods of using same
WO2000078813A2 (en) * 1999-06-18 2000-12-28 Emory University Huntington disease cellular model: stably transfected pc12 cells expressing mutant huntingtin
AU2001238347A1 (en) * 2000-02-28 2001-09-12 Hyseq, Inc. Novel nucleic acids and polypeptides
US6436703B1 (en) * 2000-03-31 2002-08-20 Hyseq, Inc. Nucleic acids and polypeptides
AU2001263006A1 (en) * 2000-05-18 2001-11-26 Hyseq, Inc. Novel nucleic acids and polypeptides
DE60141463D1 (de) * 2000-06-08 2010-04-15 Immune Disease Inst Inc Methoden und verbindungen zur hemmung immunoglobulin-vermittelter reperfusions-verletzungen
ATE449791T1 (de) * 2000-10-10 2009-12-15 Genentech Inc Inhibierung von c5 komplement-aktivierung für die behandlung und vorbeugung von xeno-transplantat oder akute vaskuläre abstossung
AU2002327164A1 (en) * 2001-01-29 2002-12-09 Idec Pharmaceuticals Corporation Engineered tetravalent antibodies and methods of use
US20040131607A1 (en) 2001-06-08 2004-07-08 Carroll Michael C. Methods and compositions for inhibiting immunoglobulin-mediated reperfusion injury
JP2005521385A (ja) * 2001-12-21 2005-07-21 ディアデクサス インコーポレーテッド 子宮内膜特異的遺伝子およびタンパク質に関する組成物および方法
AU2002364105A1 (en) * 2001-12-21 2003-07-15 Diadexus, Inc. Compositions and methods relating to endometrial specific genes and proteins
US7709610B2 (en) * 2003-05-08 2010-05-04 Facet Biotech Corporation Therapeutic use of anti-CS1 antibodies
US20100136684A1 (en) 2004-03-01 2010-06-03 Carroll Michael C Natural IgM Antibodies
CA2560066A1 (en) 2004-03-01 2005-09-15 The Cbr Institute For Biomedical Research, Inc. Natural igm antibodies and inhibitors thereof
US7612181B2 (en) * 2005-08-19 2009-11-03 Abbott Laboratories Dual variable domain immunoglobulin and uses thereof
IT1395574B1 (it) 2009-09-14 2012-10-16 Guala Dispensing Spa Dispositivo di erogazione

Also Published As

Publication number Publication date
EP2290077A2 (en) 2011-03-02
JP2011139704A (ja) 2011-07-21
JP5618852B2 (ja) 2014-11-05
AU2005219839B2 (en) 2011-11-24
EP1725659B1 (en) 2011-02-09
EP1725659A2 (en) 2006-11-29
EP2290077B1 (en) 2016-01-27
DE602005026260D1 (de) 2011-03-24
WO2005085288A2 (en) 2005-09-15
WO2005085288A3 (en) 2006-08-03
IL177825A (en) 2013-02-28
US9914751B2 (en) 2018-03-13
EP2290077A3 (en) 2011-05-18
US7442783B2 (en) 2008-10-28
US20050276811A1 (en) 2005-12-15
US20160280740A1 (en) 2016-09-29
JP2008504807A (ja) 2008-02-21
AU2005219839A1 (en) 2005-09-15
AU2005219839B9 (en) 2011-12-22
IL177825A0 (en) 2006-12-31
HK1154904A1 (en) 2012-05-04
JP2014155497A (ja) 2014-08-28
ATE498010T1 (de) 2011-02-15
US20090176966A1 (en) 2009-07-09
US20140127214A1 (en) 2014-05-08
US20170342109A1 (en) 2017-11-30
JP5557982B2 (ja) 2014-07-23
US9657060B2 (en) 2017-05-23

Similar Documents

Publication Publication Date Title
US9914751B2 (en) Natural IGM antibodies and inhibitors thereof
US7875259B2 (en) Biological materials and methods useful in the diagnosis and treatment of diseases
TR201812636T4 (tr) İnsan anti-tau antikorları.
KR20230082071A (ko) SARS-CoV-2 변이체들에 특이적으로 결합하는 항체
US20100136684A1 (en) Natural IgM Antibodies
AU2012200909B2 (en) Natural lgM antibodies and inhibitors thereof
CN1977043B (zh) 天然IgM抗体及其抑制剂
HK1154904B (en) Natural igm antibodies and inhibitors thereof
EP1286682B1 (en) Methods and compositions for inhibiting immunoglobulin-mediated-reperfusion injury
KR20220163625A (ko) 신규한 코로나-19 바이러스 표적 인간 항체
HK1150533A (en) Methods and compositions for inhibiting immunoglobulin-mediated reperfusion injury
NZ618046A (en) Fc receptor binding proteins

Legal Events

Date Code Title Description
EEER Examination request
FZDE Discontinued

Effective date: 20140402